HIV rebound in HIV controllers is associated with a specific fecal microbiome profile

Eur J Immunol. 2024 Aug;54(8):e2350809. doi: 10.1002/eji.202350809. Epub 2024 May 10.

Abstract

HIV infection is associated with gut dysbiosis, and microbiome variability may affect HIV control when antiretroviral therapy (ART) is stopped. The TLR7 agonist, vesatolimod, was previously associated with a modest delay in viral rebound following analytical treatment interruption in HIV controllers (HCs). Using a retrospective analysis of fecal samples from HCs treated with vesatolimod or placebo (NCT03060447), people with chronic HIV (CH; NCT02858401) or without HIV (PWOH), we examined fecal microbiome profile in HCs before/after treatment, and in CH and PWOH. Microbiome diversity and abundance were compared between groups to investigate the association between specific phyla/species, immune biomarkers, and viral outcomes during treatment interruption. Although there were no significant differences in gut microbiome diversity between people with and without HIV, HCs, and CH shared common features that distinguished them from PWOH. there was a trend toward greater microbiome diversity among HCs. Treatment with vesatolimod reduced dysbiosis in HCs. Firmicutes positively correlated with T-cell activation, while Bacteroidetes and Euryarchaeota inversely correlated with TLR7-mediated immune activation. Specific types of fecal microbiome abundance (e.g. Alistipes putredinis) positively correlated with HIV rebound. In conclusion, variability in the composition of the fecal microbiome is associated with markers of immune activation following vesatolimod treatment and ART interruption.

Keywords: Fecal microbiome; HIV controllers; HIV‐1 rebound; Immune activation; TLR7; Vesatolimod.

MeSH terms

  • Adult
  • Dysbiosis* / immunology
  • Dysbiosis* / microbiology
  • Feces* / microbiology
  • Female
  • Gastrointestinal Microbiome* / drug effects
  • Gastrointestinal Microbiome* / immunology
  • HIV Infections* / drug therapy
  • HIV Infections* / immunology
  • HIV Infections* / microbiology
  • HIV-1 / immunology
  • Humans
  • Male
  • Middle Aged
  • Pteridines
  • Retrospective Studies
  • Toll-Like Receptor 7 / immunology
  • Viral Load / drug effects

Substances

  • vesatolimod
  • Toll-Like Receptor 7
  • TLR7 protein, human
  • Pteridines

Grants and funding